GlaxoSmithKline’s (GSK) triple therapy for chronic obstructive pulmonary disease (COPD) has been approved ... beta2 agonist offers a more convenient treatment option, delivered by GSK’s ...

Chiesi is hoping real world evidence will show its latest COPD triple therapy can help cut hospital admissions for the disease. Trimbow (beclometasone+formoterol+glycopyrronium) combines an ...

Background: Rifabutin has been found to be effective in multi-resistant patients after various treatment cycles for ... A 7-day rifabutin-based triple therapy associated to amoxicillin and ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Researchers at Baylor College of Medicine showed ...